It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician’s choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22–0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28–0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA (GRID:grid.10698.36) (ISNI:0000000122483208)
2 Medical Oncology Department and D3i, Institut Curie, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384)
3 University Hospitals Leuven, Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338)
4 Massachusetts General Hospital Cancer Center, Harvard Medical School, Department of Hematology/Oncology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
5 Centre Eugène Marquis, Department of Medical Oncology, Rennes, France (GRID:grid.417988.b) (ISNI:0000 0000 9503 7068)
6 Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France (GRID:grid.417829.1) (ISNI:0000 0000 9680 0846)
7 University of Colorado Anschutz Medical Campus, Division of Medical Oncology, Department of Medicine, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X)
8 Oncologisch Centrum, UZ Brussel, Medical Oncology Department, Brussels, Belgium (GRID:grid.411326.3) (ISNI:0000 0004 0626 3362)
9 Miami Cancer Institute, Miami, USA (GRID:grid.418212.c) (ISNI:0000 0004 0465 0852)
10 University of California San Francisco Helen Diller Family Comprehensive Cancer Center, Department of Medicine, San Francisco, USA (GRID:grid.511215.3) (ISNI:0000 0004 0455 2953)
11 University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
12 Winship Cancer Institute, Emory University, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
13 Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA (GRID:grid.411588.1) (ISNI:0000 0001 2167 9807)
14 Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Department of Medicine and Research, Frankfurt, Germany (GRID:grid.411588.1)
15 Gianni Bonadonna Foundation, Medical Oncology, Milan, Italy (GRID:grid.411588.1)
16 Institut Jules Bordet and l’Université Libre de Bruxelles, Medical Oncology Department, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746)
17 Gilead Sciences, Inc, Department of Biostatistics, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)
18 Gilead Sciences, Inc, Department of Clinical Research, Morris Plains, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)
19 Gilead Sciences Inc, Department of Clinical Development, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)
20 Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Vall d´Hebron Institute of Oncology (VHIO), International Breast Cancer Center, Quirón Group, Barcelona, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)